دورية أكاديمية
Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia.
| العنوان: | Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia. |
|---|---|
| المؤلفون: | Mesfin EA; Addis Ababa University, Department of Microbial, Cellular and Molecular Biology, Addis Ababa, Ethiopia.; Ethiopian Public Health Institute, Addis Ababa, Ethiopia., Beyene D; Addis Ababa University, Department of Microbial, Cellular and Molecular Biology, Addis Ababa, Ethiopia., Tesfaye A; Addis Ababa City Administration Health Bureau Health Research and Laboratory Services, Addis Ababa, Ethiopia., Admasu A; St. Peter Hospital, Addis Ababa, Ethiopia., Addise D; Ethiopian Public Health Institute, Addis Ababa, Ethiopia., Amare M; Ethiopian Public Health Institute, Addis Ababa, Ethiopia., Dagne B; Ethiopian Public Health Institute, Addis Ababa, Ethiopia., Yaregal Z; Ethiopian Public Health Institute, Addis Ababa, Ethiopia., Tesfaye E; Ethiopian Public Health Institute, Addis Ababa, Ethiopia., Tessema B; Department of Medical Microbiology, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia. |
| المصدر: | PloS one [PLoS One] 2018 Jun 04; Vol. 13 (6), pp. e0197737. Date of Electronic Publication: 2018 Jun 04 (Print Publication: 2018). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: San Francisco, CA : Public Library of Science |
| مواضيع طبية MeSH: | Antitubercular Agents/*therapeutic use , HIV Infections/*drug therapy , Mycobacterium tuberculosis/*drug effects , Tuberculosis, Multidrug-Resistant/*drug therapy, Ethambutol/therapeutic use ; Ethiopia/epidemiology ; Female ; HIV Infections/epidemiology ; HIV Infections/microbiology ; Humans ; Isoniazid/therapeutic use ; Male ; Mycobacterium tuberculosis/pathogenicity ; Pyrazinamide/therapeutic use ; Rifampin/therapeutic use ; Risk Factors ; Sputum/microbiology ; Streptomycin/therapeutic use ; Tuberculosis, Multidrug-Resistant/epidemiology ; Tuberculosis, Multidrug-Resistant/microbiology |
| مستخلص: | Background: Multidrug drug-resistant tuberculosis (MDR-TB) is a major health problem and seriously threatens TB control and prevention efforts globally. Ethiopia is among the 30th highest TB burden countries for MDR-TB with 14% prevalence among previously treated cases. The focus of this study was on determining drug resistance patterns of Mycobacterium tuberculosis among MDR-TB suspected cases and associated risk factors. Methods: A cross-sectional study was conducted in Addis Ababa from June 2015 to December 2016. Sputum samples and socio-demographic data were collected from 358 MDR-TB suspected cases. Samples were analyzed using Ziehl-Neelsen technique, GeneXpert MTB/RIF assay, and culture using Lowenstein-Jensen and Mycobacterial growth indicator tube. Data were analyzed using SPSS version 23. Results: A total of 226 the study participants were culture positive for Mycobacterium tuberculosis, among them, 133 (58.8%) participants were males. Moreover, 162 (71.7%) had been previously treated for tuberculosis, while 128 (56.6%) were TB/HIV co-infected. A majority [122 (54%)] of the isolates were resistant to any first-line anti-TB drugs. Among the resistant isolates, 110 (48.7%) were determined to be resistant to isoniazid, 94 (41.6%) to streptomycin, 89 (39.4%) to rifampicin, 72 (31.9%) to ethambutol, and 70 (30.9%) to pyrazinamide. The prevalence of MDR-TB was 89 (39.4%), of which 52/89 (58.4%) isolates were resistance to all five first-line drugs. Risk factors such as TB/HIV co-infection (AOR = 5.59, p = 0.00), cigarette smoking (AOR = 3.52, p = 0.045), alcohol drinking (AOR = 5.14, p = 0.001) hospital admission (AOR = 3.49, p = 0.005) and visiting (AOR = 3.34, p = 0.044) were significantly associated with MDR-TB. Conclusions: The prevalence of MDR-TB in the study population was of a significantly high level among previously treated patients and age group of 25-34. TB/HIV coinfection, smoking of cigarette, alcohol drinking, hospital admission and health facility visiting were identified as risk factors for developing MDR-TB. Therefore, effective strategies should be designed considering the identified risk factors for control of MDR-TB. Competing Interests: All authors declare that they have no conflict of interest associated with the publication of this manuscript. |
| References: | Thorax. 2012 Jul;67(7):632-8. (PMID: 22403070) Emerg Microbes Infect. 2014 Aug;3(8):e58. (PMID: 26038753) PLoS One. 2011 Apr 19;6(4):e18614. (PMID: 21526179) J Exp Med. 2004 Sep 6;200(5):647-57. (PMID: 15353557) Antimicrob Agents Chemother. 2002 Feb;46(2):267-74. (PMID: 11796329) Ethiop J Health Sci. 2013 Nov;23(3):271-82. (PMID: 24307827) Int J Tuberc Lung Dis. 2012 Jun;16(6):805-11. (PMID: 22390880) BMC Public Health. 2015 Jul 02;15:599. (PMID: 26135909) BMC Res Notes. 2012 Aug 28;5:462. (PMID: 22929063) Trop Med Int Health. 2010 Sep;15(9):1052-66. (PMID: 20545927) Clin Microbiol Rev. 2011 Apr;24(2):314-50. (PMID: 21482728) Int J Tuberc Lung Dis. 2009 Mar;13(3):371-6. (PMID: 19275799) BMC Infect Dis. 2015 Oct 26;15:461. (PMID: 26503269) Am J Respir Crit Care Med. 2005 Sep 1;172(5):636-42. (PMID: 15947286) Int J Tuberc Lung Dis. 2009 Jan;13(1):74-8. (PMID: 19105882) BMC Public Health. 2013 Aug 28;13:782. (PMID: 23981845) Ethiop Med J. 2008 Jul;46(3):219-25. (PMID: 19271385) BMC Res Notes. 2017 Jan 3;10 (1):8. (PMID: 28057041) Tubercle. 1985 Sep;66(3):219-25. (PMID: 3931319) Eur Respir J. 2011 Sep;38(3):516-28. (PMID: 21828024) Indian J Med Res. 2011 Mar;133:312-5. (PMID: 21441686) Lancet. 2006 Nov 4;368(9547):1575-80. (PMID: 17084757) J Clin Microbiol. 2012 Nov;50(11):3712-6. (PMID: 22972826) S Afr Med J. 2009 Nov;99(11):785-7. (PMID: 20218473) J Infect Dis. 2008 Jun 1;197(11):1493-8. (PMID: 18426366) Afr Health Sci. 2012 Sep;12(3):325-30. (PMID: 23382747) BMC Public Health. 2015 Jun 20;15:572. (PMID: 26092570) |
| المشرفين على المادة: | 0 (Antitubercular Agents) 2KNI5N06TI (Pyrazinamide) 8G167061QZ (Ethambutol) V83O1VOZ8L (Isoniazid) VJT6J7R4TR (Rifampin) Y45QSO73OB (Streptomycin) |
| تواريخ الأحداث: | Date Created: 20180605 Date Completed: 20181127 Latest Revision: 20220408 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC5986145 |
| DOI: | 10.1371/journal.pone.0197737 |
| PMID: | 29864118 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!